Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Feb 27:12:2050313X241235451.
doi: 10.1177/2050313X241235451. eCollection 2024.

Generalized pustular psoriasis successfully treated with spesolimab: A case report

Affiliations
Case Reports

Generalized pustular psoriasis successfully treated with spesolimab: A case report

Noemi Brigenti et al. SAGE Open Med Case Rep. .

Abstract

Generalized pustular psoriasis is defined as a primary, sterile, macroscopically visible pustular eruption on non-acral skin, which can occur with or without systemic inflammation and/or psoriasis vulgaris, and can either be relapsing or be persistent, according to the European Rare and Severe Psoriasis Expert Network. The treatment of generalized pustular psoriasis may be challenging. We describe a 48-year-old woman with a 15-year history of severe generalized pustular psoriasis and plaque psoriasis resistant to multiple courses of treatments with conventional and biological agents who had a rapid, complete and durable (up to 12 months) clinical remission with spesolimab, an anti-interleukin-36 receptor antagonist monoclonal antibody recently approved for the treatment of generalized pustular psoriasis flares.

Keywords: Generalized Pustular Psoriasis Physician Global Assessment; Generalized pustular psoriasis; IL-36; spesolimab.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Paolo Gisondi has been consultant in advisory board and/or served as a speaker for AbbVie, Biogen, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi, and UCB Pharma; Giampiero Girolomoni has received personal fees from AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Leo Pharma, Merck Serono, Novartis, Pfizer, Pierre Fabre, Samsung bioepis and Sanofi; Francesco Bellinato and Noemi Brigenti none declared.

Figures

Figure 1.
Figure 1.
At baseline, large and multiple erythematous plaques covered by coalescent pustules are observed on the back (a) and on the limbs (b).
Figure 2.
Figure 2.
At 2 weeks after the first spesolimab dose, complete clearance of the erythematous plaques and pustules on the back (a) and on the limbs (b); some post-inflammatory sequelae persist.

Similar articles

Cited by

References

    1. Navarini AA, Burden AD, Capon F, et al.. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 1792–1799. - PubMed
    1. Löfvendahl S, Norlin JM, Schmitt-Egenolf M. Prevalence and incidence of generalized pustular psoriasis in Sweden: a population-based register study. Br J Dermatol 2022; 186(6): 970–976. - PubMed
    1. Bachelez H, Choon SE, Marrakchi S, et al.. Inhibition of the Interleukin-36 Pathway for the treatment of generalized pustular psoriasis. N Engl J Med 2019; 380(10): 981–983. - PubMed
    1. Marrakchi S, Puig L. Pathophysiology of Generalized Pustular Psoriasis. Am J Clin Dermatol 2022; 23(Suppl 1): 13–19. - PMC - PubMed
    1. Bellinato F, Gisondi P, Marzano AV, et al.. Characteristics of patients experiencing a flare of generalized pustular psoriasis: a multicenter observational study. Vaccines (Basel) 2023; 11(4): 740. - PMC - PubMed

Publication types

LinkOut - more resources